Implantica Presents the First Quarter 2024 on May 15 at 15:00 CEST
Implantica Presents the First Quarter 2024 on May 15 at 15:00 CEST
VADUZ, Liechtenstein, May 8, 2024 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the first quarter 2024 at 15:00 CEST on May 15. The interim report for the first quarter will be published at 8:00 a.m. CEST on the same day.
列支敦士登瓦杜兹，2024 年 5 月 8 日 /PRNewswire/-- Implantica AG（publ）邀请投资者于5月15日欧洲中部标准时间 15:00 参加2024年第一季度发布会。第一季度的中期报告将于当天欧洲中部标准时间上午 8:00 发布。
The presentation will be in English via an audiocast with teleconference:
演示将以英语进行，并通过电话会议进行音频广播：
If you wish to participate via webcast, please use the following link:
如果您想通过网络直播参与，请使用以下链接：
If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.
如果您想通过电话会议参加，请在下面的链接上注册。注册后，将向您提供电话号码和会议 ID 以访问会议。
Speakers:
发言者：
- CEO Peter Forsell
- CFO Andreas Öhrnberg
- Chief Corporate Affairs Officer Nicole Pehrsson
- 首席执行官彼得·福塞尔
- 首席财务官安德烈亚斯·奥恩伯格
- 首席企业事务官 Nicole Pehrsson
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
[email protected]
欲了解更多信息，请联系：
Nicole Pehrsson，投资者关系
电话 (CH)：+41 (0) 79 335 09 49
[电子邮件保护]
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
Implantica在斯德哥尔摩的纳斯达克首个北方成长型市场上市。
The company's Certified Adviser is FNCA Sweden AB, [email protected]
该公司的认证顾问是瑞典FNCA AB，[email protected]
The information was sent for publication, through the agency of the contact person set out above, on May 8, 2024 at 2:30 p.m. CEST.
该信息已于欧洲中部夏令时间2024年5月8日下午 2:30 通过上述联系人的代理机构发送出版。
About Implantica
关于 Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information.
Implantica是一家医疗科技集团，致力于将先进技术引入人体。Implantica的主要产品RefluxStop是一款带有CE标志的用于预防胃食管反流的植入物，在成功的临床试验结果的支持下，它有可能改变抗反流治疗的模式。Implantica还专注于体内的电子健康，并开发了广泛的、受专利保护的产品线，部分基于两种平台技术：旨在监测各种健康参数、从体内控制治疗并与护理人员进行远程通信的eHealth平台，以及旨在通过完好无损的皮肤以无线方式为遥控植入物供电的无线能量平台。Implantica在纳斯达克第一北部超级增长市场上市（股票代码：IMP A SDB）。请访问以获取更多信息。
This information was brought to you by Cision
这些信息是由 Cision 带给你的
The following files are available for download:
以下文件可供下载：
|
Implantica presents the first quarter 2024 on May 15 at 15:00 CEST |
|
Implantica将于欧洲中部标准时间5月15日 15:00 公布2024年第一季度 |